Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. is positioned favorably due to its collaboration with Gilead, leveraging KITE cell therapy manufacturing and patient support that is expected to enhance commercial viability and market access for its therapies. The robust clinical profile of Anito-cel, which shows comparable durability to existing CAR-T therapies, underscores its potential for significant market success, particularly with projected approval in multiple myeloma patients by the end of 2026. With an estimated $7 billion in peak global sales driven by anticipated label expansions, the company is on a solid trajectory toward achieving profitability, backed by strong management execution in developing transformative immunotherapies.

Bears say

Arcellx Inc faces significant challenges that contribute to a negative outlook, including the uncertainty surrounding the successful development of its D-Domain CAR-T therapy platform and ARC-SparX platform for generating viable clinical candidates. The company's implied equity value of $7.8 billion hinges on the completion of its acquisition by GILD, which introduces substantial commercial and regulatory risks, as well as potential dilution from future financing. Additionally, competitive pressures and the possibility of underwhelming product profiles further exacerbate the inherent risks to Arcellx's valuation and stock performance.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.